Global Pharmaceutical Industry Outlook, 2024

Growing Competitive Intensity is Driving Pharma Digitization, Building Unique Growth Opportunities

The publisher identifies and defines the leading trends shaping the global pharmaceutical landscape in this analysis. The study period is 2021-2028, with 2023 as the base year and 2024-2028 as the forecast period. The geographic scope includes 5 regions: North America, Latin America (LATAM) and the Caribbean, Asia-Pacific (APAC), Europe, and the Middle East and Africa. Chemicals/Small molecules and biologics are the 2 segments covered.

Other information covered include:

• Pharmaceutical industry overview
• Revenue forecasts by segment
• The top 5 predictions for 2024 and beyond
• Macro and micro trends driving the industry’s future
• R&D expenditure and leading therapeutic areas
• Growth opportunities

After a plateaued growth in 2023 due to the biologics segment slowdown and a decrease in the uptake of COVID-19 vaccines and therapeutics, the industry will likely realign its growth to record a 5.9% CAGR between 2023 and 2028. Year-on-year (YoY) growth will remain low in developed economies, including the United States and Europe. In contrast, emerging economies in APAC, LATAM, and the rest of the world will register comparatively stronger single-digit YoY growth.

The recession and ongoing inflation will remain pressing challenges for the pharmaceutical industry in 2024, affecting returns on investment. Pharmaceutical companies will continue to shift toward regional rather than global suppliers to ensure geographic proximity and a smoother, more reliable supply chain.

There continues to be a strong focus on environmental, social, and governance commitments and supply-chain digitalization through lighthouse manufacturing techniques, decentralized clinical trial approaches, and the application of artificial intelligence. The industry is also witnessing a healthy mergers and acquisitions landscape, with several successful transactions recently. In addition, the publisher expects a rebound in initial public offerings (IPOs), with 5 IPOs completed by February 2024.